NWBO 0.61 Northwest Biotherapeutics, Inc.
| Range: | 0.2841-0.93 | Vol Avg: | 2269901 | Last Div: | 0 | Changes: | 0 |
| Beta: | -0.59 | Cap: | 0.37B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Fri Dec 14 2001 | Empoloyees: | 25 | ||
| CUSIP: | 66737P600 | CIK: | 0001072379 | ISIN: | US66737P6007 | Country: | US |
| CEO: | Ms. Linda F. Powers J.D. | Website: | https://www.nwbio.com | ||||
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow